Billionaire John Paulson is reportedly set to reap $500 million from Amgen's huge deal to acquire Horizon Therapeutics
. Amgen said Monday it will pay $116.50 a share in cash, a nearly 20% premium to Horizon's closing price of $97.29 on December 9.
Paulson & Co. is set to take about $520 million before taxes on the deal, Forbes estimated, based on publicly disclosed information. Forbes cited FactSet data in saying the firm has owned a stake in Horizon since 2017, with an estimate Paulson paid an average of about $31 for 6.1 million shares. "Its an important position for us," Paulson told Forbes in emailed comments."Excellent outcome for both companies.
Paulson & Co. is widely known for making $15 billion by shorting the US housing market at the peak of the credit bubble in 2007. The firm transitioned from a hedge fund to a family office in 2020 and now primarily invests John
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Billionaire John Paulson Stands To Make $500 Million From Horizon’s Sale To AmgenHedge fund billionaire John Paulson stands to reap about $500 million if Amgen's deal for Horizon goes through. It's the latest victory for the man who shot to fame for his big bet during the subprime crisis.
Consulte Mais informação »
Canadians have lost $500 billion in paper wealth, but there's a silver liningMaybe companies are finally ready to take the baton from Canada\u0027s over\u002Dextended households, writes Kevin Carmichael. Read on.
Consulte Mais informação »
Einride Raises $500 Million To Finance Autonomous Truck BusinessThe Swedish freight technology company says this is the largest asset-backed facility in heavy-duty electric transport to date.
Consulte Mais informação »
Amgen reportedly in talks to buy Horizon TherapeuticsThe U.S. biotechnology company AMGN was the last of three suitors standing in an auction for Horizon, according to sources cited by The Wall Street Journal.
Consulte Mais informação »
Amgen set to buy biotech firm Horizon at $26 bln valuation - Bloomberg NewsAmgen Inc is set to buy biotech firm Horizon Therapeutics Plc at a valuation of about $26 billion in what would be its largest acquisition, Bloomberg News reported on Monday.
Consulte Mais informação »
Amgen confirms to acquire Horizon Therapeutics in cash deal valued at about $27.8 billionAmgen Inc. undefined said Monday it has agreed to acquire Horizon Therapeutics Plc undefined in an all-cash deal valued at $27.8 billion, confirming earlier...
Consulte Mais informação »